Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs

[1]  S. Kaveri,et al.  Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting , 2015, Acta naturae.

[2]  S. Zamvil,et al.  Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets , 2015, European Neurology.

[3]  E. N. Lebedenko,et al.  Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering , 2015 .

[4]  M. Dubina,et al.  Liposome-encapsulated peptides protect against experimental allergic encephalitis , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  M. Krumbholz,et al.  B cells and antibodies in multiple sclerosis pathogenesis and therapy , 2012, Nature Reviews Neurology.

[6]  A. Tonevitsky,et al.  Design of Targeted B Cell Killing Agents , 2011, PloS one.

[7]  P. Sørensen,et al.  The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.

[8]  A. Kozyr,et al.  Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  R. Fischer,et al.  Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin , 2008, Journal of Neuroimmunology.

[10]  M. Wilm,et al.  Legionella pneumophila glucosyltransferase inhibits host elongation factor 1A , 2006, Proceedings of the National Academy of Sciences.

[11]  A. Lutterotti,et al.  Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments , 2006, Journal of Neuroimmunology.

[12]  P. Baeuerle,et al.  Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. , 2003, International immunology.

[13]  M. Reindl,et al.  Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis , 2001, Multiple sclerosis.

[14]  Ira Pastan,et al.  Immunotoxin therapy of cancer. , 1993, Nature reviews. Cancer.

[15]  D. Hafler,et al.  Multiple sclerosis. , 2012, The Journal of clinical investigation.